Clinical Trials Browser

Phase 1/2 × Breast Neoplasms × exemestane × Clear all

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Breast

Breast Neoplasms

NCT00905021 2020-07-24

EXTENT

Phase 1/2 Terminated

4 enrolled 6 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02983604 2019-08-07

GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

Phase 1/2 Terminated

14 enrolled 13 charts

Breast

Breast Neoplasms

NCT01484041 2018-02-09

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Phase 1/2 Terminated

12 enrolled 7 charts

Breast

Breast Neoplasms

NCT01202591 2016-02-11

GLOW

Phase 1/2 Completed

127 enrolled 8 charts

Breast

Breast Neoplasms

NCT00931450 2013-08-12

Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer

Phase 1/2 Unknown

70 enrolled

Breast

Breast Neoplasms

NCT00417885 2010-09-21

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

Phase 1/2 Terminated

6 enrolled 6 charts

Breast

Breast Neoplasms

Clinical Trials

PIKALO-1

MORPHEUS HR+BC

EXTENT

GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

GLOW

Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer